Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Neoplasm Metastasis 7Carcinoma, Non-Small-Cell Lung 6Triple Negative Breast Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Skin Neoplasms 3Melanoma 3Head and Neck Neoplasms 3Breast Neoplasms 3Recurrence 2Prostatic Neoplasms 2Ovarian Neoplasms 2Neoplasms 2Mycosis Fungoides 2Multiple Myeloma 2Lymphoma, T-Cell 2Lymphoma, Large-Cell, Anaplastic 2Lymphoma, Follicular 2Lymphoma, B-Cell 2Glioblastoma 2Colorectal Neoplasms 2Advanced Malignancies 2Uveal Melanoma 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Stomach Neoplasms 1Recurrent Squamous Cell Carcinoma of Head 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Myelodysplastic Syndromes 1

Interventions

pembrolizumab 2cemiplimab 1Nivolumab 1Fluorouracil 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Malignant Solid Tumor × cemiplimab × Clear all
NCT03192345 2024-08-07

A First-in-human Study of the Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of SAR439459 Monotherapy and Combination of SAR439459 and Cemiplimab in Patients With Advanced Solid Tumors

Sanofi

Phase 1 Completed
161 enrolled
Other solid neoplasm

Malignant Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡